Introduction {#sec1-1}
============

Resistance of the malaria and tubercle bacilli has thwarted the objective of attainment of good health for all the people of the world. Tuberculosis (TB) remains a worldwide public-health problem, despite the fact that the causative organism was discovered more than 100 years ago and highly effective drugs and vaccines are available. Eradication of this disease does not appear to be an attainable goal for decades to come.

TB was declared a global health emergency by the World Health Organization (WHO) in 1993. This has been mainly due to the emergence of Multiple Drug Resistant (MDR) strains and the synergy between tubercle bacilli and HIV. According to WHO, 1.7 billion persons (1/3 of world\'s population) harbor tuberculosis bacilli, 8-10 million new cases appear annually and some 3 million die of TB every year. About five people succumb to this dreaded disease every minute globally and every seventh patient of TB in the World is an Indian. 500,000 deaths from this disease occur in India every year. It is estimated that between 2002 and 2020 approximately, a billion people will be newly infected, over 150 million people will get sick, and 36 million people will die of TB if proper control measures are not instituted.\[[@ref1]\]

Concept of *Naimittika Rasayana* is a unique concept in Ayurveda, proved for its beneficial role in the patients suffering from chronic diseases in promoting vitality, and ability to withstand the devastating effects of these diseases. This concept brings a new dimension into the health-care, and promotes an integrated approach between different modalities in the field of medicine.\[[@ref2]\]

Ayurveda has described a large number of *Rasayana*, which can provide protection against toxic substances and diseases. They promote both physical and mental-health, improve the status of the *Dhatu* (tissues), confer immunity and rejuvenate the system.\[[@ref3]\] The *Rasayana* of Ayurveda and the chemotherapeutic drugs of modern medicine, used in combination, will not only promote healing may also improve vitality in these patients.

So the present study has been carried out to establish that *Bhringarajasava*, improves immunity in patients with pulmonary tuberculosis (PTB) and pacifies the side-effects of the chemotherapeutic agents of anti-TB treatment i.e. Directly Observed Treatment Short-course chemotherapy (DOTS) regime. And to establish the specific symptomatology of *Rajayakshma* (Pthisis) described in Ayurveda on clinical basis in PTB patients.

Materials and Methods {#sec1-2}
=====================

Drugs {#sec2-1}
-----

*Bhringarajasava* is a compound herbal formulation consisting of *Bhringaraja* (*Eclipta prostrate* Linn.), as active ingredient along with *Haritaki* (*Terminalia chebula* Retz.), *Pippali* (*Piper longum* Linn.), *Jatiphala* (*Myristica fragrance Houtt*.), *Lavanga* (*Sygizium aromaticum* Linn.), *Twak* (*Cinnamomum zeylanicum*), *Ela* (*Elatteria cardamomum*), *Tamalapatra* (*Cinnamomum tamala*), *Nagakesara* (*Messua ferrea*), and *Gudam* (old cane jaggery).\[[@ref4]\] It is prepared by dissolving jaggery in the juice of *Bhringaraja* (watery extract) and adding coarse powders of the remaining drugs. It is allowed to ferment in a vessel, resulting in an *Asava* (fermented liquid preparation) after the period of 1 month.

Selection of the patients {#sec2-2}
-------------------------

Sixty patients of different age groups were selected after obtaining informed consent. Sampling of the patients done based on the inclusion and exclusion criterion. Details of criteria are given in [Table 1](#T1){ref-type="table"}.

###### 

Inclusion and exclusion criteria
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Diagnosis {#sec2-3}
---------

Patients were diagnosed based on the Revised National TB Control Programme (RNTCP) pattern\[[@ref5][@ref6]\] by the Medical Officer -- TB Control, State TB Training and Demonstration Centre (STDC), S.R. Nagar, Hyderabad.

Treatment regime {#sec2-4}
----------------

\(i\) Administration of *Bhringarajasava*:Dosage: 30 ml with equal quantity of water, thrice a day Time of administration: ½ an hour after food (*Prana Vayu Kala*)Duration: 2-3 months during the intensive phase of DOTSFollow-up: 6-8 months based on treatment category.(ii) Method of allocation:The study is a non-randomized controlled open trial. Sixty patients were divided into two equal groups, Test Group (TG) and Control Group (CG) c onsidering the design of the study. Both the groups were given standard RNTCP regimen i.e., DOTS chemotherapy regime, whereas TG patients were additionally given adjuvant drug i.e., *Bhringarajasava*. Details are given in [Table 2](#T2){ref-type="table"}.

###### 

Treatment allocation
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DOTS-Category wise treatment regime {#sec2-5}
-----------------------------------

Based on RNTCP treatment protocols, duration and treatment regime was decided. DOTS category and corresponding treatment regime are listed\[[@ref6]\] in [Table 3](#T3){ref-type="table"}.

###### 

Directly observed treatment short-course category and treatment regime
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Assessment criteria {#sec2-6}
-------------------

Both the subjective and objective parameters were taken into consideration to assess the severity of the disease and response of the adjuvant treatment.

### Subjective parameters {#sec3-1}

The symptomatology of *Rajayakshma* (pthisis) is discussed in groups i.e., *Trirupa* (symptom triad), Shadrupa (group of six symptoms), *Ekadasarupa* (group of 11 symptoms) in Ayurveda. These were used as subjective parameters\[[@ref7]\]

*Amsaparsabhitapah* (Pain in costal and scapular region)*Santapakarapadayoh* (Burning sensation in palms and soles)*Jwara* (Pyrexia)*Bhaktadwesha* (Anorexia)*Swasa* (Dyspnoea)*Kasa* (Cough)*Shonita darsanam* (Hemoptysis)*Swarabheda* (Hoarseness of voice)*Anilath shula* (Pain in visceral organs)*Samkochamsaparshyoh* (Shoulder and scapular emaciation)*Daha* (Burning sensation)*Atisara* (Diarrhea)*Pittat raktasya chagama* (Hematemesis)*Sirasah paripoornata* (Heaviness in the head)*Kantadwamsa* (Tracheal shift)

### Objective parameters {#sec3-2}

\(1\) Weight (2) Sputum for Acid Fast Bacilli (AFB) (3) Chest X-ray (CXR) (Skiagram) - Clinical assessments are made before, during and at the end of the treatment with the follow-up for 6 or 8 months.

Gradation of results {#sec2-7}
--------------------

Marked: Complete relief in subjective parameters (75-100%) with sputum conversion, weight gain (≥8 kg on average) and resolution of changes in skiagrams.

Moderate: Max. Relief in subjective parameters (50-75%) with sputum conversion, weight gain (5-8 kg on average) and mild changes in skiagrams.

Mild: 25-50% relief in subjective parameters with sputum conversion, weight gain (≤5 kg on average) and no changes in skiagrams.

Poor: Up to 25% relief in subjective parameters with sputum conversion, weight gain (\<5 kg on average) and no changes in skiagrams.

Observations and Results {#sec1-3}
========================

The demographic data in relation to sex, age, socio-economic status, immunization status (Bacillus Calmette Guerin \[BCG\] vaccination) and observations on subjective parameters and objective parameters were presented in the Tables [4](#T4){ref-type="table"}-[12](#T12){ref-type="table"}.

###### 

Incidence of gender
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###### 

Incidence of age
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###### 

Incidence of socio-economic status
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###### 

Immunization status
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###### 

Incidence of clinical features
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###### 

Results-category-I
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###### 

Results-category-II
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###### 

Results-category-III
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###### 

Objective parameter-weight

![](Ayu-33-523-g012)

[Table 4](#T4){ref-type="table"} implies that there is not much gender variation in the incidence of the disease.

Of the total, 50 cases (83.33%) belong to age group below 40 years. This observation supports the knowledge that pulmonary TB (PTB) is commonly a disease of the young adults \[[Table 5](#T5){ref-type="table"}\].

Socio-economic status has pivotal role in the causation of disease. It is very clear that almost 90% of the cases belong to the poor and lower-middle class. These ratios may vary in other studies, since this study was conducted on the indigent population, the ability of whom to afford private care is compromised \[[Table 6](#T6){ref-type="table"}\].

[Table 7](#T7){ref-type="table"} gives an idea of role of BCG vaccination in prevention of the disease and the number of people who have not been immunized so far. Protection from PTB following BCG vaccination is only 50%.

Among the observed 13 symptoms, the percentage of relief was more than 75% in the TG patients (except in shoulder and scapular emaciation). In the CG, relief was mild (marked relief in the control of temperature).

The subjective relief in the TG patients of category-II was marked. There was a mild improvement in the CG patients. *Atisara, Pittatraktasya Chagama* symptoms improved in both groups; *Swarabheda* in CG patients and *Kantadwamsam* in TG patients were not observed in the treatment category-II.

Complete relief of symptoms was observed in TG.

In the treatment category-1, the mean weight in CG patients before and after treatment was 42.87 and 46.56 (difference of 3.69), whereas in TG patients this was 47.06 and 52.18 (difference of 5.12). The improvement in weight gain in TG patients is statistically significant (t~30~ = 2.25, *P* \< 0.05, significant at 5% level).

In the treatment category-II, the mean weight in CG patients before and after treatment is 39.54 and 44.00 (difference of 4.46) whereas in TG patients this value is 45.90 and 52.45 (difference of 6.55). The improvement in weight gain in TG patients is statistically not significant (t~20~ = 1.77, *P* \> 0.05). Even though this change is statistically not significant, it was observed that the maximum weight gain was 12 kg.

In the treatment category-III, the mean weight in CG patients before and after treatment was 44.66 and 48.33 (difference of 3.67) whereas in TG patients this value was 43.33 and 50.66 (difference of 7.33). The improvement in weight gain in TG patients is statistically significant (t~4~ = 5.02, *P* \< 0.01, significant at 1% level).

Objective parameter -- Sputum for AFB {#sec2-8}
-------------------------------------

All the TG patients are reported with sputum conversion within the stipulated time i.e. after intensive phase of treatment whereas 10 patients out of 30 cases (6 CAT-I, 4 CAT-2) of CG were placed on the prolongation phase.

Objective parameter -- Skiagrams {#sec2-9}
--------------------------------

CXR was not given much importance in Sputum + ve cases (Cat-I and Cat-II) and it was given importance for the CAT-III patients (6) i.e., Sputum 蜢ve cases. However, the observations made on the skiagrams of 22 patients (TG patients-3 Cat-III + 3 Cat-II + 6 Cat-1 and CG patients-3 Cat-III, 3 Cat-II, 4 Cat-I) before and after treatment is being presented in [Table 13](#T13){ref-type="table"}.

###### 

Objective parameter-CXR

![](Ayu-33-523-g013)

Discussion {#sec1-4}
==========

*Rajayakshma* (Pthisis) is described in Ayurveda with specific reference to etiology (*Nidana Chatushka*) and symptomatology. These correspond to the clinical experience in PTB.

Stage-I is *Trirupavasta* (symptom triad) which corresponds to Cat-III patients (sputum 蜢ve); stage-II is *Shadrupavastha* (group of six symptoms) and corresponds to Cat-I patients (sputum + ve) and stage-III is 5-8 symptoms of *Ekadasarupas* (group of 11 symptoms) and corresponds to Cat-II patients (with relapse). Complete establishment of *Ekadasarupas* is the stage with complications, as in MDR TB (Cat-IV) patients.

The *Lakshanas* of *Kaphaja Krimi* (mucosal bacteria) seems to resemble *Mycobacterium tuberculosis* and its effect on the patient. The ingredients of *Bhringarajasava* possess properties of *Krimighna* (anti-bacterial) and *Kshayahara*. The purpose of selecting *Bhringarajasava* as *Naimittika Rasayana* was fulfilled by these criteria.

Results were statistically analyzed in relation to treatment categories mentioned under RNTCP.

Subjective parameters {#sec2-10}
---------------------

*Amsaparsabhitapah* (Pain in costal and scapular region): This symptom was observed in all the 60 patients, but it has no reference in texts in modern medicine. The relief in this symptom after treatment was around 35% in CG patients and was 100% in TG patients.*Samtapakarapadayoh* (Burning sensation in palms and soles): Relief from this symptom in TG patients is about 75% in comparison to 50% in CG patients (Complete relief in Cat-III patients of CG).*Jwara* (Pyrexia): There was complete abatement of febrile morbidity in TG patients over the CG (\<75% improvement on average).*Bhaktadwesha* (Anorexia): In TG patients there was increased appetite (almost 100%) whereas mild improvement in appetite was observed in some cases of CG.*Swasa* (Dyspnea): Marked relief in the TG patients (\>90%) whereas it was \<65% in CG.*Kasa* (Cough): Cough progressively diminished and ultimately became occasional and non-productive with easy expectoration within the 15 days of treatment in TG patients and moderate relief was observed in CG over the period of 6-8 months.*Shonita Darshanam* (Hemoptysis): The relief from this symptom was not statistically significant (\<5 cases) in the CG. These patients were given another modern drug to control the bleeding. However, encouraging results were observed in TG patients.*Swarabheda* (Hoarseness of voice): The relief from this symptom was also statistically insignificant as it was observed in few cases (only six cases). Better relief in TG patients can be attributed to the lessening of cough and easy expectoration within 15 days.*Anilath Shula* (Pain in visceral organs): Presence of this symptom implies the early involvement of visceral organs as systemic manifestation of the disease. The complete relief from this symptom in TG patients could be explained by improved appetite and better absorption and assimilation of digested foods.*Sankochamsaparshyoh* (Shoulder and scapular emaciation): This symptom was clearly observed in Cat-II patients, which implies that the manifestation of this symptom is chronic in nature. Relief from this symptom occurs with increase in bulk of muscles in the body, over a period of time. This was very encouraging in TG patients over the CG.*Daha* (Burning sensation): There was complete relief from this symptom in TG patients.*Atisara* (Diarrhea): No TG patients were reported with this symptom during the treatment.*Pittaraktasyachagama* (Hematemesis): This symptom was observed only in two cases and was controlled immediately in TG patient.*Sirasaha paripoonata* (Heaviness in the head): This symptom was manifested due to *Kapha Dosha* predominance. All the TG patients were relieved from this symptom within 10 days of treatment and 3-4 months' duration in the CG patients.*Kantadwamsa* (Tracheal shift): This was observed only in one case with fibrosed and consolidated lung.

Objective parameters {#sec2-11}
--------------------

Weight: In some patients of CG, further weight loss occurred, but in the TG none experienced weight loss and every patient gained a minimum of 5 kg weight. This was statistically highly significant in Cat-III patients (*P* \< 0.01), statistically significant in Cat-I patients (*P* \< 0.05) and statistically not significant in Cat-II patients (*P* \> 0.05). The maximum weight gain observed was 12 kg.Sputum for AFB: All the TG patients were reported with sputum conversion within the stipulated time i.e., after intensive phase of treatment. Ten patients out of 30 (6 CAT-I, 4 CAT-II) in the CG were placed on the prolongation phase.Skiagram (CXR): Density of the opacity in the CXR was less than on previous studies, with lessening of the cavities and resolution of fibrotic changes noted in the TG patients.

In summary, the addition of supportive therapy with *Bhringarajasava* ensures increased appetite and creates a general sense of subjective well-being. Additionally, it controls temperature elevation, promotes weight gain, abolishes night sweats, reduces cough, and encourages expectoration. The response in TG patients of Cat-I was optimum and moderate in CG patients. Moderate improvement was seen in TG patients of Cat-II as compared to mild improvement in CG patients. Substantial improvement was observed in TG patients of Cat-III in comparison with poor improvement in CG patients. The same was shown in [Table 14](#T14){ref-type="table"}.

###### 

Final result
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Probable mode of action {#sec2-12}
-----------------------

*Bhringarajasava* improves immunity and enhances the defensive mechanism of the body. Stimulation of the Reticulo Endothelial System (RES) activates the mesenchyme and accelerates healing at the tubercular sites. In turn, this process results in destruction of killer cells and formation of new healthy tissue.\[[@ref8]\]

Addition of *Bhringarajasava* to DOTS offers hepato protection due to the presence of Wedelolactone -- Hepatoprotective principle present in the leaves of *Bhringaraja*. It has immunomodulatory properties, which create the subjective well-being and cause remarkable changes in the objective parameters. The concept of *Naimittika Rasayana* is well-known in the field of Ayurveda in the treatment of chronic disorders.\[[@ref9][@ref10]\]

Weight loss and cachexia in PTB points to the presence of cytokine and tumor necrosis factor-α (TNF-α), in addition to the immuno-pathological effects, such as tissue necrosis and fever.\[[@ref11]\]

*Bhringarajasava* possesses dynamic properties and is capable of correcting and restoring errors of the *Koshtagni* and *Dhatuagni* (metabolic and digestive fire in the tissues). Its other properties include include *Balyam* (nutritive), *Brimhanam* (tonic), *Rasayanam* (Rejuvenative), *Hridyam* (cardiotonic), *Vishaharam* (anti-toxic) and *Krimighnam* (anti-bacterial).

Conclusion {#sec1-5}
==========

*Naimittika Rasayana*, plays a complementary, adjuvant, supportive role in the management of communicable diseases. Utilization of this modality in the practice of modern medicine appears to be minimal. This study offers an opportunity to incorporate a herbal rejuvenative in the management of PTB, a chronic debilitating disorder, the incidence and devastating effects of which is on the rise, especially, with the emergence of resistant tubercle bacilli. It is the fervent hope of the participants of this study that mainstream medicine will give serious consideration to the availability of other such products in the vast Pharmacopoeia of Ayurveda, which can substantially enhance the effect of the drugs in its armamentarium.

The purpose of this supportive therapy is to improve the resistance of the patient to damage caused by the tubercle bacilli, and to create an environment in the body unsuitable for proliferation of the bacilli.

The aforesaid properties of the *Bringarajasava* are invaluable, not only for correcting low vitality state and predisposition for TB but also in treatment of the disease. *Bhringarajasava* can be easily administered as an adjunct to DOTS. DOTS drugs are known to cause hepatotoxicity. Improved weight gain in TG patients in comparison to CG indicates the supportive effect of *Bhringarajasava* and its regulatory effect on the activity of TNF-α.
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